Abstract: The present disclosure provides a method for producing a microchannel device, which can form a channel that has high hydrophobicity, high solvent resistance as well, and also resistance to heat and damage, on demand with high accuracy, and produces the microchannel device at a low cost, while having high productivity. The method for producing a microchannel device includes: forming a channel pattern from a hydrophobic resin on a porous substrate by an electrophotographic method; melting the channel pattern by heat to allow the channel pattern to permeate into the porous substrate, thereby forming a channel in the inside of the porous substrate.

Abstract: A locking mechanism includes a first member that is provided on one side to lock and is rotated about a rotating shaft, a second member that is provided on the other side to lock and comes into contact with the first member to rotate the first member, a rotation applying member that further applies a rotational force to the first member rotated by the second member, a restriction portion that restricts movement of the first member to be rotated in a direction in which the first member is released from a locked state, and an elastic portion that allows the first member and the restriction portion to be in elastic contact with each other and allows the first member and the restriction portion to start to be in elastic contact with each other before the first member rotated by the second member is further rotated by the rotation applying member in a release direction which is the direction in which the first member is released from the locked state.

Abstract: A server device configured to communicate, via a communication network, with at least one device including a learner configured to perform processing by using a learned model, includes processor, a transmitter, and a storage configured to store a plurality of shared models pre-learned in accordance with environments and conditions of various devices. The processor is configured to acquire device data including information on an environment and conditions from the at least one device, and select an optimum shared model for the at least one device based on the acquired device data. The transmitter is configured to transmit a selected shared model to the at least one device.

Abstract: An apparatus includes a housing, a cover that is opened and closed on the housing, a detection part that detects opening and closing of the cover using ON and OFF, a rotating part that is rotatably supported and turns on and off the detection part, a pushing portion that comes into contact with the rotating part to rotate the rotating part in a case where the cover is closed, and a rotation applying part that applies a rotational force to the rotating part rotated by the pushing portion in a direction in which the detection part is turned on in a case where the cover is closed.

Abstract: Provided is a compound and so on having aldehyde dehydrogenase 2 (ALDH2) activation effect. A compound, a pharmaceutically acceptable salt of the compound, or a prodrug of the compound or the salt, the compound being represented by the following formula (1): wherein A is a heterocycle, R1 and R2 are each independently hydrogen, an alkyl, an alkenyl, or an alkynyl. R3 is an alkyl, ac alkenyl, or as alkynyl, and X1 and X2 are each independently a halogen.

Abstract: An object of the present invention is to provide a compound having CK1? inhibition activity and/or ALK5 inhibition activity and the like. The object thereof can be attained by a compound represented by the following formula (1): wherein R1 to R10 each independently represent hydrogen, alkyl, cycloalkyl, or a halogen, wherein R2 and R3 or R4 and R5 together with two carbon atoms to which they are attached form a 5-membered ring containing one heteroatom selected from the group consisting of an oxygen atom, a nitrogen atom, and a sulfur atom, optionally substituted with alkyl; or a pharmaceutically acceptable salt thereof, wherein the compound excludes 2-[4-(2,3-dihydro-5-benzofuranyl)-2-(1,1-dimethylethyl)-1H-imidazol-5-yl]-6-methylpyridine.

Abstract: The present invention provides a compound represented by formula (1): or pharmaceutically acceptable salt thereof, wherein X and Y are the same or different from each other and represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group, wherein the C1-6 alkoxy group may be substituted with a C1-6 alkoxy group, and Z and W are the same or different from each other and represent a hydrogen atom, a halogen atom, or a C1-6 alkyl group.

Abstract: The present invention provides a compound represented by formula (1): or pharmaceutically acceptable salt thereof, wherein X and Y are the same or different from each other and represent a hydrogen atom, a halogen atom, a C1-6 alkyl group, or a C1-6 alkoxy group, wherein the C1-6 alkoxy group may be substituted with a C1-6 alkoxy group, and Z and W are the same or different from each other and represent a hydrogen atom, a halogen atom, or a C1-6 alkyl group.

Abstract: A compound represented by the formula (I) or a salt thereof: wherein a ring Z is a 5 to 6-membered heteroaromatic ring having one or two heteroatoms in the ring; X1 is a hydrogen atom, a hydroxy group, a hydroxy C1-6 alkyl group, —B(OH)2, a boronate ester group, a cyclic boronate ester group, a boranyl group, a cyclic boranyl group, —BF3Mn1, —Sn(R12)(R13)(R14), a leaving group, a carboxy group, a formyl group, or —NR16R17; and X2 is a hydrogen atom or —CO2R18.

Abstract: A compound represented by the formula (I) or a salt thereof: wherein a ring Z is a 5 to 6-membered heteroaromatic ring having one or two heteroatoms in the ring; X1 is a hydrogen atom, a hydroxy group, a hydroxy C1-6 alkyl group, —B(OH)2, a boronate ester group, a cyclic boronate ester group, a boranyl group, a cyclic boranyl group, —BF3Mn1, —Sn(R12)(R13)(R14), a leaving group, a carboxy group, a formyl group, or —NR16R17; and X2 is a hydrogen atom or —CO2R18.

Abstract: A compound represented by Formula (1), or a pharmacologically acceptable salt thereof retains the principal therapeutic effect of paroxetine and has an improved CYP inhibitory effect: wherein R1 is a hydrogen atom or C1-6 alkyl group.

Abstract: The present invention provides a novel compound having FGFR inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. Specifically, the present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein n represents 0 to 2; A represents an arylene group or a heteroarylene group; G represents a single bond, an oxygen atom or —CH2—; E represents a nitrogen-containing non-aromatic heterocycle; R1 represents an alkoxy group or the like; R2 represents a hydrogen atom or the like; and R3 represents a hydrogen atom, an alkyl group, an alkoxy group or the like, with the proviso that when E represents an azetidine ring and R2 or R3 is present on a nitrogen atom on the azetidine ring, the R2 or R3 does not represent a hydrogen atom.

Abstract: An object of the present invention is to provide an antifungal agent which has excellent antifungal effects and is superior in terms of its physical properties, safety and metabolic stability. According to the present invention, there is disclosed a compound represented by the following formula (I), or a salt thereof: wherein R1, R2, X, Y, ring A, Z, R3 and R4 are as defined in the specification.

Abstract: The present invention provides a novel compound having FGFR inhibitory activity or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the same. Specifically, the present invention provides a compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof: wherein n represents 0 to 2; A represents an arylene group or a heteroarylene group; G represents a single bond, an oxygen atom or —CH2—; E represents a nitrogen-containing non-aromatic heterocycle; R1 represents an alkoxy group or the like; R2 represents a hydrogen atom or the like; and R3 represents a hydrogen atom, an alkyl group, an alkoxy group or the like, with the proviso that when E represents an azetidine ring and R2 or R3 is present on a nitrogen atom on the azetidine ring, the R2 or R3 does not represent a hydrogen atom.

Abstract: A compound represented by formula (1-1) or (1-2), or a pharmacologically acceptable salt thereof retains the principal therapeutic effect of sitaxentan and has an improved CYP inhibitory effect: wherein R1 is a halogen atom, etc., R2 is a methyl group, etc., R3 is a C1-6 alkyl group, etc., and M is a group represented by: etc.

Abstract: A production method of a compound containing a primary, secondary, or tertiary aminomethyl aromatic ring of the present invention includes: using a fluoroboron compound or a dimer thereof, or solvates thereof, which are represented by a formula (I): Ra(Rb)N—CH2—BF3M??(I) as an aminomethylating agent for an aromatic ring; and reacting the aminomethylating agent with an aromatic ring-containing compound, which can react with the aminomethylating agent, under the presence of a metal catalyst such as a palladium compound so as to perform the direct aminomethylation of the aromatic ring.

Abstract: Anti-fungal agent having excellent anti-fungal action physicochemical properties including safety and water solubility.

Abstract: The present invention provides an antifungal agent which has excellent antifungal action, and which is also excellent in terms of its properties, and in particular its solubility in water and safety. The present invention discloses a compound represented by the following formula (I) or a salt thereof: wherein R1, R2, R3 and R4 are defined in the specification; one of X and Y is a nitrogen atom, and the other is a nitrogen atom or an oxygen atom; ring A represents a 5- or 6-member heteroaryl ring or benzene ring which may have 1 or 2 halogen atoms or C1 to C6 alkyl groups; and Z represents a single bond, a methylene group, an ethylene group, an oxygen atom, a sulfur atom, —CH2O—, —OCH2—, —NH—, —CH2NH—, —NHCH2—, —CH2S—, or —SCH2—.

Abstract: Provided is a fluoroboron compound which is highly safe and stable and is capable of forming a cyclic ether-fused ring by the intramolecular alkoxymethylation reaction, or a salt thereof. The compound can be synthesized by the intramolecular alkoxymethylation reaction of a fluoroboron compound represented by the formula (I) or a salt thereof in the presence of a metal catalyst. (wherein the moiety represented by the formula represents an aromatic ring; L represents a substituent such as a halogen atom; R represents a substituted or unsubstituted alkylene group having 1 or 2 carbon atoms; and M represents an alkali metal cation or the like, with the proviso that L and —R—OCH2BF3M are respectively located on contiguous carbon atoms on the aromatic ring, or in the case of a fused aromatic ring, on two carbon atoms adjacent to one carbon at the fused position).

Abstract: The present inventors succeeded in isolating GWT1 (PfGWT1), which is one of the enzymes involved in GPI biosynthesis in the malaria parasite P. falciparum. In addition, the inventors revealed that degenerate mutant DNAs, with a lower AT content than the DNA encoding the PfGWT1 protein, can complement the phenotype of GWT1-deficient yeast. Based on the findings, the present invention provides the GWT1 protein of malaria parasites and the use of the protein in methods of screening for antimalarial drugs. The present invention also provides degenerate mutant DNAs encoding proteins involved in GPI biosynthesis, and which have a lower AT content than the original DNAs. The present invention also provides methods of screening for antimalarial drugs which use the degenerate mutant DNAs.